Qyuns Therapeutics (HKG:2509) has granted Caldera Therapeutics an exclusive right to develop and commercialize QX030N globally under an out-license agreement, a Thursday Hong Kong bourse filing said.
The biotechnology company will receive a one-time upfront payment of $10 million under the contract, as well as around 24.88% equity interest in Caldera Therapeutics.
The firm may also receive additional milestone payments of up to $545 million and tiered royalties.
QX030N is a long-acting bispecific antibody in the pre-clinical stage for the treatment of immunologic disorders.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。